Japan vs Oman: Statin use vs. average non-HDL cholesterol levels

Japan
3.4
in 2018
Oman
3.4
in 2018
Japan rank
75th
Oman rank
75th

Statin use vs. average non-HDL cholesterol levels over time

  • Japan
  • Oman
01234198019992018

How they compare

Japan currently reports 3.4 against 3.4 in Oman, a difference of 0.

The two have swapped places 1 time across 39 shared years of data; in 1980 it was Japan ahead.

Japan ranks 75th and Oman ranks 75th of 191 countries.

Across the 4 decades both report, Japan averaged higher in 1 and Oman in 3.

Head to head by decade

Decade Japan Oman Difference Ahead
1980s 3.5 3.48 0.02 Japan
1990s 3.5 3.77 0.27 Oman
2000s 3.5 3.74 0.24 Oman
2010s 3.42 3.53 0.1111 Oman

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Japan or Oman?
Japan, at 3.4 against 3.4 in Oman as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Japan and Oman?
0, with Japan ahead.
How many years of comparable data are there for Japan and Oman?
39 years are reported by both, from 1980 to 2018.
How do Japan and Oman rank globally for statin use vs. average non-hdl cholesterol levels?
Japan ranks 75th and Oman ranks 75th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.